Baxter International Hits New 52-Week Low at $16.08

Baxter International, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 16.08 as of March 20, 2026. This significant decline marks a stark contrast to the company's 52-week high of USD 34.52, reflecting a challenging year for the stock, which has seen a performance drop of 50.9% over the past year. The company's market capitalization stands at approximately USD 11.79 billion, with a price-to-earnings ratio of 46.00. Despite a dividend yield of 1.56%, Baxter has faced difficulties in maintaining financial stability, evidenced by a high debt-to-equity ratio of 1.23 and a concerning debt-to-EBITDA ratio of 3.86 times. Baxter's recent financial results have shown a decline in key metrics, including a 26.29% drop in net sales to USD 2.81 billion and a 45.07% decrease in pre-tax profit to USD 156 million. The company has reported negative results for three consecutive quarters, contributing to its underperformance against the S&P 500, which has gained 14.9% during the same period.